4527 On Other Exchanges
Symbol
Exchange
4527 is not on other exchanges.

rohto pharmaceutical co ltd (4527) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ROHTO PHARMACEUTICAL CO LTD (4527)

Related News

No related news articles were found.

rohto pharmaceutical co ltd (4527) Related Businessweek News

No Related Businessweek News Found

rohto pharmaceutical co ltd (4527) Details

Rohto Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. It offers eye care products, such as eye drops and contact lens; oral medicines comprising gastrointestinal medicines, Chinese herbal medicines, and supplements; dermal medications; regenerative medicines; and non-prescription medicines. The company also operates beauty counters that provide skin care products under the episteme, Obagi, and Hada-Labo brands, as well as beauty care treatments. In addition, it operates an online store, as well as a restaurant, an urban vegetable farm, and a relaxation salon. Rohto Pharmaceutical Co., Ltd. has a partnership agreement with Osaka University's Graduate School of Medicine for the commercialization of mesenchymal stem-cell-based regenerative treatments. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co., Ltd. in 1949. Rohto Pharmaceutical Co., Ltd. was founded in 1899 and is headquartered in Osaka, Japan.

6,642 Employees
Last Reported Date: 06/22/16
Founded in 1899

rohto pharmaceutical co ltd (4527) Top Compensated Officers

Chairman of the Board of Directors and Chief ...
Total Annual Compensation: ¥160.0M
Compensation as of Fiscal Year 2016.
rohto pharmaceutical co ltd
Rohto Pharmaceutical Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2016; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2017; Declares Dividend for the Six Months Ended September 30, 2016, Payable from December 8, 2016; Provides Dividend Guidance for the Year Ending March 31, 2017

Rohto Pharmaceutical Co., Ltd. reported consolidated earnings results for the six months ended September 30, 2016. For the period, the company reported net sales of JPY 71,298 million, operating income of JPY 6,465 million, ordinary income of JPY 6,822 million and profit attributable to owners of the parent of JPY 4,191 million or JPY 36.68 per diluted share as compared to net sales of JPY 77,341 million, operating income of JPY 7,173 million, ordinary income of JPY 7,509 million and profit attributable to owners of the parent of JPY 4,873 million or JPY 42.70 per diluted share for the same period a year ago. Profit before income taxes was JPY 6,123 million compared to JPY 7,231 million a year ago. Net cash provided by operating activities was JPY 3,524 million compared to JPY 5,493 million a year ago. Purchase of property, plant and equipment was JPY 1,617 million compared to JPY 2,284 million a year ago. Purchase of intangible assets was JPY 93 million compared to JPY 89 million a year ago. The company provided consolidated earnings guidance for the year ending March 31, 2017. For the year ending March 31, 2017, the company expects net sales of JPY 150,500 million, operating income of JPY 13,100 million, ordinary income of JPY 13,400 million and profit attributable to owners of the parent of JPY 7,500 million or JPY 65.88 per share as compared to net sales of JPY 163,000 million, operating income of JPY 15,500 million, ordinary income of JPY 15,200 million and profit attributable to owners of the parent of JPY 9,500 million or JPY 83.47 per share as previously guided. The company declared a dividend of JPY 10.00 per share for the six months ended September 30, 2016 compared to JPY 10.00 per share paid a year ago. Scheduled date of dividend payment is from December 8, 2016. The company provided dividend guidance for the year ending March 31, 2017. For the year ending March 31, 2017, the company expects to pay a dividend of JPY 11.00 per share.

Rohto Pharmaceutical Co., Ltd. Presents at 2016 World Alliance Forum in San Francisco, Nov-22-2016 11:35 AM

Rohto Pharmaceutical Co., Ltd. Presents at 2016 World Alliance Forum in San Francisco, Nov-22-2016 11:35 AM. Venue: The Golden Gate Club, San Francisco, California, United States. Speakers: Masayo Yumoto, Group Leader, Regenerative Medicine Research & Planning Division.

Rohto Pharmaceutical Co., Ltd. Presents at Nomura Investment Forum 2016, Nov-28-2016

Rohto Pharmaceutical Co., Ltd. Presents at Nomura Investment Forum 2016, Nov-28-2016 . Venue: Hotel Chinzanso Tokyo, 10-8, Sekiguchi 2-Chome, Bunkyo-Ku, 112-8680 Tokyo, Japan.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4527 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4527.
View Industry Companies
 

Industry Analysis

4527

Industry Average

Valuation 4527 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ROHTO PHARMACEUTICAL CO LTD, please visit www.rohto.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.